For example, SEs are quite CDK7-dependent, and, in cancer, the treatment of cells with the CDK7 inhibitor THZ1 reduces the recruitment of SE-driven oncogenic transcription factors and suppresses the expression of these associated oncogenes [58–61]. This evidence concerns the gene CDK7 and cancer.